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We have investigated for the first time the pathway of internalization and final fate of a specific 
metal-organic framework (MOF) in cells. We have based our study on two calcein loaded UiO-66 
samples with particles size of 150 and 260 nm (i.e. cal@150UiO-66 and cal@260UiO-66, 
respectively). Our study shows that the active trafficking of cal@150UiO-66 was done almost 
exclusively through clathrin-mediated endocytosis, whereas the uptake of cal@260UiO-66 was a 
combination of both clathrin and caveolae-mediated endocytosis. Co-localization studies with a 
lysosomal marker showed that cal@150UiO-66 was located mostly in lysosomes for further 
degradation, whereas cal@260UiO-66 seemed to avoid the lysosomal degradation and potentially 
deliver the cargo molecules in the cytosol, allowing their distribution to different cellular organelles. 
This study reveals the importance of the internalization processes of MOFs, particularly the 
relevance of their particle size, and also the critical significance of their final fate to become an 
efficient drug delivery system. Based on these results, it is possible that extremely small particle 
sized MOFs are not the most efficient carriers and instead, relatively medium size particles are 
required.     
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1. Introduction 
Modern society has been coping with new and complex diseases. Traditional drugs in the form of 
small molecules serve their therapeutic effect by circulating in the blood stream at very high 
concentrations. Thus, drugs are able to reach a specific organ or tissue in the desired final amount. 
In these conditions, healthy tissue damage, local or systemic toxicity, more frequent doses and 
associated side effects are however almost unavoidable. Nanomedicine has become an attractive 
alternative to overcome these problems by reducing the side effects of free drugs through slow 
release, targeted delivery, and protection from degradation.[1] Different nano-sized preparations 
have been studied and some are currently in the market, including the liposome based Doxil and 
DaunoXome, albumin-based particles Abraxane, and PEGylated proteins such as Oncospar, PEG-
Intron, PEGASYS and Neulasta, demonstrating the potential of this approach.[2,3]  
In this context, metal-organic frameworks (MOFs) have emerged recently as a promising 
alternative for drug delivery application. This is due to their particular characteristics of high pore 
volume, large surface areas, multiple topologies and tunable pore size and surface chemistry.[4,5] 
Different therapeutic compounds have been loaded in these materials with positive results. Among 
others, Morris et al. have loaded and delivered the vasodilator gas nitric oxide (NO) for its use in 
applications such as antibacterial, antithrombotic and wound- healing;[6] Lin et al. described the use 
of MOFs for the co-delivery of the anticancer cisplatin molecule and siRNA to enhance the 
therapeutic effect;[7] Horcajada et al. have encapsulated several anticancer and antiviral agents into 
MOFs and also performed the post synthetic modification of coating a Fe-based MOF with heparin 
to improve its biological properties.[8,9] One of the major advantages of these carriers compared 
with traditional drug delivery systems (e.g. liposomes, micelles, zeolites, mesoporous silica 
nanoparticles, etc.) is their high loading capacity. We have shown, carrying out a computational 
screening study, that MOFs can encapsulate up to 2 g of drug per gram of porous material, a much 
higher capacity than the maximum amount loaded in mesoporous silicas and organic carriers – 
typically up to 0.3 mg/g.[10,11] Although the fast kinetic release of drugs from crystalline MOFs still 
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remains a limitation for drug delivery applications, we have demonstrated recently that amorphous 
MOFs can solve this issue. Indeed, we showed how by loading a drug in a MOF, followed by the 
collapse of the porosity around the drug through a mechanical amorphization process, it was 
possible to extend the drug release time from 2 to more than 30 days in systems of around 250 nm 
size, small enough to cross the cell membrane.[12]      
 In order to develop efficient and successful MOF systems for drug delivery it is not only 
important to study the loading and release of different therapeutic compounds, but also to 
understand the mechanisms of cellular uptake and intracellular fate. Molecules generally enter cells 
by passive diffusion, whereas nanoparticles usually need an energy dependent method called 
endocytosis.[13,14] This cellular mechanism has attracted the attention of many scientists within the 
field. However, different research groups have shown that establishing general rules for the 
optimization of the cellular internalization of particles is a complex task due to a variety of factors. 
These factors include the rate and endocytic pathway selection, which is extremely cell line 
dependent, and specific characteristics of the materials, such as size, shape, surface charge and 
surface chemistry.[15,16] For example, Chithrani et al. demonstrated that the uptake of gold 
nanoparticles of 50 nm was more efficient than smaller or larger particles on HeLa cells.[17] On the 
other hand, Win et al. showed that polystyrene nanoparticles of 100 nm were internalized more 
efficiently than the 50 and 200 nm particles on adenocarcinoma cells.[18] Understanding the 
different mechanism of endocytosis and how MOFs interact with the cellular membrane and finally 
enter cells is therefore a key task for optimizing drug delivery systems.  
When studying the cellular uptake, we can define two types: phagocytosis (i.e. “cell eating”) 
and pinocytosis (i.e. “cell drinking”), more commonly known also as endocytosis.[19] The former 
refers to the process of engulfing foreign large particles (> 0.5 µm) and is carried out by the 
phagocytosis specialists, macrophages and neutrophils,[20] whereas pinocytosis is used for 
internalizing fluid surrounding the cell and thus all the molecules and small particles in the fluid 
phase.[15] In turn, there are 3 main endocytosis pathways which are classified depending on the 
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proteins involved: i) clathrin, ii) caveolae, and iii) clathrin and caveolae-independent endocytosis 
such as macropinocytosis.[19,20] Clathrin-mediated endocytosis is the most understood metabolic 
pathway, where cellular receptors recognize and internalize particles into 60-200 nm protein 
(clathrin) coated vesicles called early endosomes. These endosomes become mature vesicles or late 
endosomes that fuse with lysosomes, provoking the degradation of the drug delivery system and 
potentially the loaded cargo, thus undermining or totally voiding its therapeutic effect. On the other 
hand, caveolae-mediated endocytosis is related to the clustering of lipid rafts forming flask shape 
invaginations in the cell membrane. Finally, in clathrin and caveolae-independent endocytosis, the 
cargo is absorbed through 0.5-1.0 µm vesicles in a non-specific way, and is therefore found in 
almost all cells types.[13] Understanding the factors that affect the endocytosis mechanism of MOFs 
is critical to design new drug delivery systems able to avoid lysosomal degratation that may prevent 
the MOF and drug action before degradation. 
 In this work, we aim to understand the trafficking mechanism and possible fate of MOFs 
after cellular internalization, as well as proposing the set-up of techniques and parameters for these 
studies using MOFs. Here, we used a calcein loaded Zr-based MOF, UiO-66 (UiO = University of 
Oslo), which has been used by others and ourselves as a drug delivery vehicle for the release of 
different drugs into cells.[12,21,22] We studied the different endocytosis pathways for the uptake of 
two different UiO-66 samples with different particle size by HeLa cells, a tumoral cervical 
epithelial culture frequently used for in vitro studies, in the presence and absence of different 
endocytosis pharmacological inhibitors. We used Fluorescence-Activated Cell Sorting (FACS) to 
measure the internal cellular fluorescence, followed by confocal microscopy to determine the 
intracellular location of the loaded UiO-66. 
2. Results and Discussion 
We choose UiO-66, [Zr6O4(OH)4(BDC)6] (BDC = 1,4-benzenedicarboxylate), in this study because 
of the low toxicity of Zr. Indeed, zirconyl acetate shows a lethal dose, LD50, of ca. 4.1 mg/ml in 
rats; the human body contains ca. 300 mg of Zr, and the daily amount ingested is ca. 3.5 mg/day.[23] 
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Additionally, we have seen that IC50 value for UiO-66 on HeLa cells is 1.503 ± 0.154 mg/mL after 
24 hours of exposure. [12] UiO-66 has a cubic structure based on Zr oxo-clusters and BDC ligands, 
and possesses high thermal and chemical stability combined with a large porosity (SBET = 1200 m2g-
1
, Vp = 0.5 cm3g-1) formed by two main cavities of ca. 11 and 8 Å diameter.[12,24–26] In this work, we 
used two different protocols for UiO-66 synthesis in order to obtain two samples with different 
particle size. In order to analyze the endocytosis mechanism used by HeLa cells to incorporate UiO-
66, we loaded the two UiO-66 samples with a fluorescent molecule, calcein. We chose this 
molecule as a model because it can be easily detected by FACS and confocal microscopy. Also, it is 
hydrophilic, so it cannot cross the cell membrane and consequently it requires a drug delivery 
system to be transported inside the cells. Due to its self-quenching characteristics, high local 
concentrations of calcein (e.g. as loaded in a MOF before being delivered) cannot be detected, and 
therefore will only be observed when is released from the solid.[27] This last characteristic do not 
interfere with any of the experiments shown in this work as the kinetics of calcein release from this 
material are fast, reason why it is possible to observe the calcein signal after 2 hours of incubation. 
Figure S1 (electronic supporting information, ESI) shows the powder X-ray diffraction (PXRD) 
pattern of both synthesized UiO-66 and calcein loaded UiO-66 samples, confirming the crystalline 
structure before and after the loading. Figure S2 shows the scanning electron microscopy (SEM) 
images, indicating a particle size of 153 ± 2 and 261 ± 7 nm for both samples, named here 150UiO-
66 and 260UiO-66, respectively. Additionally, the colloidal characterization of the particles was 
determined in growth media and PBS (ESI, S3). The measurements showed a particle size of 156 ± 
6 and 275 ± 53 nm for 150UiO-66 and 260UiO-66 in growth media, respectively. This confirms that 
the particles maintained the same particle size range in the solution where the experiments were 
performed. The themogravimetric analysis (TGA) of UiO-66 (Figure S4) showed a first step at 100 
ºC corresponding to the solvent molecules desorption, followed by the solid degradation at 450 ºC. 
Additionally, the calcein loaded materials, denoted as cal@150UiO-66 and cal@260UiO-66, 
presented another step at ca. 350°C corresponding to calcein leaving the solid. The amount of 
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calcein loaded in the materials was ca. 7 and 10 ± 2 wt.% for 150UiO-66 and 260UiO-66 respectively. 
It is important to emphasize that in order to have comparable results between both UiO-66 samples 
in the following experiments, the amount of calcein used was either the same for both samples or 
the results were normalized with respect to the control sample. This means that the results are not 
affected by the different fluorescent intensities of the samples.  
2.1. Evaluation of energy dependence 
In order to asses if the internalization of UiO-66 was an energy dependent process, i.e. endocytosis, 
rather than passive diffusion, we incubated the HeLa cells with either cal@150UiO-66 or 
cal@260UiO-66 at 37 °C and 4 °C. It is well know that many proteins and metabolic pathways are 
sensitive to temperature, and therefore active processes are reduced at low temperature.[31] Figure 1 
shows the comparison of internal fluorescence, measured by FACS, of HeLa cells incubated with 
cal@150UiO-66 and cal@260UiO-66 at 37 °C and 4 °C. The internalization of both UiO-66 samples 
was greatly inhibited at low temperature, and the uptake was ca. 75 % lower than the control (at 
37 °C). This result confirms that the uptake mechanism used by cells for the internalizing the MOF 
particles is through endocytosis and not by simple passive diffusion. Similar results have been 
reported for other types of nanoparticles such us silicas and carboxylated polystyrene 
nanoparticles.[28–30] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effect of temperature (37 °C, control, and 4 °C) on cal@150UiO-66 and cal@260UiO-66 
uptake after 1.5 h incubation, measured by FACS. The statistical significance was determined by 
using Student’s t test, and is indicated in the graph: **P < 0.01, ****P < 0.0001. 
cal@150UiO-66
cal@260UiO-66
Control, 37 ºC 4 ºC
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2.2. Effect of different endocytosis inhibitors on the uptake of cal@UiO-66 
We then evaluated the effect of different pharmacological inhibitors in order to understand the 
endocytic pathway used for HeLa cells on the uptake of UiO-66. First, we used sucrose and 
chlorpromazine to inhibit clathrin-mediated endocytosis. Sucrose is involved in the dispersion of 
clathrin matrices on the cell membrane, whereas chlorpromazine inhibits clathrin disassembly and 
receptor recycling to the membrane during clathrin-mediated endocytosis.[30,31] Second, we used 
nystatin, a polyene antibiotic, for preventing caveolae-mediated endocytosis by sequestration of 
cholesterol from the cell membrane.[31] Third, rottlerin was employed to avoid intake by 
micropinocytosis through inhibition of kinases proteins.[32] As positive controls for the inhibitors, 
we used specific tracers proven to selectively enter into cell through a specific pathway: transferrin 
and ceramide for clathrin and caveolae-mediated endocytosis, respectively, and dextran for 
macropinocytosis.[30,33] We evaluated the uptake of UiO-66 in the presence of the inhibitors after a 
short exposure time (2 h) as confusing results may be generated when longer periods are used. This 
is because the inhibition of one endocytic pathway may activate compensatory uptake mechanisms, 
as has been reported previously.[31] Also, metabolic processes and membrane integrity in unhealthy 
cells would be altered and therefore the results may induce artifacts, so it is important to work in a 
concentration range where cells are not going to suffer any damage. To define suitable working 
concentrations, cytotoxicity analyses were carried out after 2 h of exposure to the inhibitors.  
Figure 2 shows the metabolic activity of HeLa cells after 2 h of exposure to the different 
pharmacological endocytosis inhibitors measured by the bioreduction of a tetrazolium compound 
(MTS) into a formazan colored product, known as MTS assay. According to this, we established the 
working concentrations for sucrose and nystatin as 102.7 mg/mL (0.3M) and 250 µg/mL 
respectively. These values were selected based on the values found in literature for this kind of 
experiments, as these two compounds did not present a negative effect on cell viability in the 
concentration range tested.[31,33,34] The concentrations for chlorpromazine and rottlerin were set at 
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31.9 µg/mL (100 µM) and 2.6 µg/mL (5 µM), respectively. In this case, we selected the maximum 
concentration that exhibits the lowest detrimental effect on cell viability.  
 
 
Figure 2. Metabolic activity of HeLa cells after 2 h of exposure to different pharmacological 
endocytosis inhibitors measured by MTS assay: a) sucrose, b) chlorpromazine, c) nystatin, and 
d) rottlerin. 
 
Figure 3 shows the normalized internal fluorescence, obtained through FACS, of HeLa cells 
after the uptake of the two UiO-66 samples with different particle size in the presence of inhibitors. 
The uptake of cal@150UiO-66 after exposure to sucrose and chlorpromazine (i.e. clathrin-mediated 
endocytosis inhibitors) was 20%, whereas exposure to nystatin (i.e. caveolae-mediated endocytosis 
inhibitor) had a minor effect (ca. 89 %), and rottlerin (i.e. micropinocytosis inhibitor) decreased the 
uptake to ca. 42 %. For cal@260UiO-66, the uptake after the exposure to sucrose and 
chlorpromazine decreased to ca. 46 and 59 %, respectively, whereas nystatin and rottlerin inhibited 
a) b) 
c) d) 
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the uptake to ca. 79 % and 64 %, respectively. The decrease on uptake to 20 % when blocking the 
clathrin-mediated process suggests that the trafficking of small cal@150UiO-66 particles are 
following this pathway, whereas there was no statistical difference with control cells when 
caveolae-mediated endocytosis was inhibited. On the contrary, cal@260UiO-66 uptake was highly 
inhibited when both caveolae- and clathrin-mediated endocytosis were blocked. These results 
indicate that the UiO-66 internalization pathway is affected by the size of the particles: the 
trafficking of cal@150UiO-66 is done almost exclusively through the clathrin pathway, whereas the 
internalization of cal@260UiO-66 is a combination of both clathrin and caveolae-mediated 
endocytosis. In addition, part of the trafficking for UiO-66 with both particle sizes is made through 
macropinocytosis, as the internalization is affected by the presence of rottlerin. Nevertheless, this is 
a non-selective mechanism to internalize large quantities of solution, independently of the cargo. [35] 
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Figure 3. Effects of pharmacological endocytosis inhibitors on the uptake of cal@150UiO-66 and 
cal@260UiO-66, measured by FACS. The statistical significance was determined by using ordinary 
one-way ANOVA, and is indicated in the graph: (**P < 0.01, ****P < 0.0001). 
 
2.3. Effect of incubation time on the uptake of cal@UiO-66 
Since the uptake kinetics of clathrin-mediated endocytosis is faster than caveolae-mediated, we 
wanted to study the effect of incubation time in order to support our endocytic pathway usage 
analysis. Figure 4a shows the internal fluorescence values for both UiO-66 samples with different 
particle size during a time frame between 15 min and 3 h, whereas Figure 4b represents the 
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normalized uptake values with respect to the 3 h uptake. As expected, the internalization of UiO-66 
of both particle sizes was time dependent, showing a positive trend on the values of internal 
fluorescence over time. The cellular uptake efficiency (i.e. the total amount) for cal@260UiO-66 was 
higher than for cal@150UiO-66 for all the times measured (Figure 4a). This was independent from 
the fact that in the experiments the amount of 150UiO-66 was higher than 260UiO-66 in order to keep 
the same amount of calcein in both samples and to be able to compare both results. Nevertheless, 
cal@150UiO-66 was internalized faster than cal@260UiO-66 (Figure 4b). Indeed, the uptake of 
cal@150UiO-66 was ca. 60 % at 30 min, whereas cal@260UiO-66 reaches this value after 2 h. These 
results based on the kinetics of the endocytosis process further support the clathrin-mediated route 
for cal@150UiO-66, whereas the caveolae-mediated route plays an important role for cal@260UiO-
66. 
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Figure 4. Kinetics of cal@150UiO-66, open circles, and cal@260UiO-66, black circles, uptake 
measured by FACS. a) Cytosolic fluorescence after incubation for different times, and 
b) normalized values, where fluorescence of cells treated for 3 h was considered as 100 %. 
 
2.4. Intracellular localization of UiO-66 by using endocytic tracers 
We used laser confocal microscopy to determine if the loaded UiO-66 particles were located in the 
same intracellular vesicles as some specific tracers well known for their preferential endocytic 
pathway selection: transferrin, ceramide and dextran to stain clathrin-mediated endocytosis, 
caveolae-mediated endocytosis and macropinocytosis vesicles, respectively. Figures 5a and 5b 
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show the confocal images of Hela cells incubated with cal@150UiO-66 and cal@260UiO-66, 
respectively, and with either transferrin or ceramide. In Fig. 5a, top, the yellow staining coming 
from the overlap of the green (i.e. calcein) and red (i.e. transferrin) fluorescence indicates a high 
correlation between the intracellular location of cal@150UiO-66 and clathrin-mediated vesicles, 
whereas in Fig. 5a, middle, only a small correlation between cal@150UiO-66 and caveolae-mediated 
(i.e. ceramide) vesicles is observed. Additionally, in Fig. 5a, bottom, a moderate degree of co-
localization was observed for macropinocytosis (i.e. dextran). On the other hand, we also observed 
a high degree of co-localization between cal@260UiO-66 and clathrin-mediated (i.e. transferrin) 
vesicles (Fig. 5b), cal@260UiO-66 and caveolae-mediated (i.e. ceramide) vesicles and cal@260UiO-
66 and macropinocytosis vesicles. We quantified these results by measuring the Manders’ overlap 
coefficient (MOC), which varies from 0 for non-overlapping images to 1, for complete co-
localization (Figure 5c).[36,37] The values obtained confirmed the higher degree of co-localization of 
cal@150UiO-66 and transferrin and dextran compared to ceramide, with values of 0.57, 0.48 and 
0.15, respectively. The analysis also proved the high correlation between cal@260UiO-66 and the 
three tracers, with values of 0.52, 0.36 and 0.37 for transferrin, ceramide and dextran, respectively. 
The small decrease (10.5 %) in the MOC when transferrin was incubated together with cal@260UiO-
66 compared to cal@150UiO-66 showed no statistical significance. However, for ceramide, there 
was a substantial increment (56.3 %) in the MOC when it was incubated along cal@260UiO-66 in 
comparison to cal@150UiO-66. This further supports the fact that in the case of particles smaller 
than 200 nm, clathrin-mediated endocytosis is preferred over caveolae-mediated pathway, whereas 
for particles larger than 200 nm the latter becomes also relevant. Finally, both particles are 
internalized non-specifically by macropinocytosis as shown in section 2.2. 
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Figure 5. Confocal microscopy images of cells incubated with a) cal@150UiO-66, and 
b) cal@260UiO-66, showing green fluorescence (i.e. calcein), and either transferrin (top, 100 
µg/mL) or ceramide (bottom, 3.5 µg/mL), showing red fluorescence. c) Mander’s overlapping 
coefficient for both UiO-66s samples and tracers. Error bars represent the standard error of at least 
10 independent images. 
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2.5. Effect of the internalization pathway on the final processing and fate of UiO-66 
After endocytosis occurs, the internalized drug delivery vehicle (i.e. the MOF particles) and drug 
molecules are processed via different metabolic pathways by transporting the vesicles to the correct 
intracellular organelle.[38] It is believed that caveolae-mediated endocytosis vesicles, compared with 
the more classical clathrin-mediated, can avoid the lysosomes.[13] This theory is based on pathogen 
studies, where some viruses and bacteria come into cells through this way bypassing the digestion 
in the lysosomes.[39] Based on this idea, MOF particles should be internalized by the caveolae-
mediated pathway in order to avoid the lysosomal acidic degradation and to have a higher chance to 
deliver the cargo in other intracellular location without degradation. We therefore wanted to 
investigate the fate of the UiO-66 particles after the endocytosis process, and particularly whether 
the MOF particles were located in the lysosomes for further acidic degradation or not. In order to 
determine if the concentration of MOF affected the formation of lysosomes, we incubated the cells 
with different concentrations of empty 150UiO-66 and 260UiO-66, together with a lysosome marker 
(LysoTracker®-Deep red, Life Technologies). Figure 6 shows the confocal images of HeLa cells 
treated for 2 h with different concentrations of both UiO-66 samples, and then stained with 
LysoTracker®-Deep red. There was a significant increment in the number of lysosomes when the 
cells were incubated with 0.05 mg/mL of MOF compared with the control (i.e. cells incubated only 
with LysoTracker®-Deep red) for both 150UiO-66 and 260UiO-66, something that was further 
intensified when the concentration was increased up to 0.5 mg/mL, but was then stabilized at 1 
mg/mL. Also, it was not possible to determine at this point differences between the two UiO-66 
samples with different particle size. 
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Figure 6. Effect of UiO-66 concentration in the formation of lysosomes. Confocal microscopy 
images of HeLa cells incubated for 2 h either with empty 150UiO-66 or 260UiO-66 and then for 30 
min with LysoTracker®-Deep red (red fluorescence). 
 
 
 Figure 7a shows the confocal microscopy images used to carry out the co-localization 
studies, using LysoTracker®-Deep red, to determine the rate of both cal@UiO-66 samples located 
in the lysosome. After 2 h of incubation, we found a high level of co-localization between 
cal@150UiO-66 and LysoTracker®-Deep red, represented by the yellow color in the merged images, 
whereas we only found a moderate degree of correlation for cal@260UiO-66. Quantification analysis 
using the MOC confirmed these results. Indeed, the co-localization degree for cal@260UiO-66 was 
ca. 37 % lower than for cal@150UiO-66, which indicates that later is located mostly in lysosomes 
for further degradation whereas cal@260UiO-66 seems to successfully evade these compartments 
and potentially delivers cargo molecules in the cytosol.  
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Figure 7. a) Confocal microscopy images of HeLa cells incubated with cal@150UiO-66 or 
cal@260UiO-66 (green fluorescence, i.e. calcein), and LysoTracker®-Deep red (red fluorescence), 
for 2 h. b) Manders’ overlapping coefficient for both UiO-66 samples and the lysosome marker. 
Error bars represent the standard error of at least 10 independent images. 
 
 Based on these results, it is possible that extremely small particle sized MOFs are not the 
most efficient carriers and instead, relatively medium size particles are required. Endosomal or 
lysosomal escape needs to be taken in account for the use of these materials in drug delivery 
application as particles trapped inside vesicles are not contributing to the final goal of delivering the 
cargo molecules in the cytosol. MOFs with special features that allow them to avoid or escape from 
a) 
b) 
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the lysosome need to be developed as it has been done with other kind of nanoparticles. For 
example, Carregal-Romero et al. where able to synthesized particles that avoided the lysosomal 
degradation by NIR-light activated delivery.[40] Also, some nanoparticles sensitive to pH have been 
shown to be able to deliver the guest molecules in the cytosol.[41,42] Finally, these findings highlight 
the necessity of an in-depth study of particle characteristics, such particle size, external surface 
chemistry, and intracellular fate in the design of MOFs for drug delivery application. 
 
3. Conclusion 
In this work, we have studied the effect of particle size on the trafficking and subsequently 
processing of calcein loaded UiO-66 of two different sizes, 150 and 260 nm, on HeLa cells. Our 
results show that cellular internalization of UiO-66 into HeLa cells is an energy dependent process 
and it is also determined by the particle size of the solids. Clathrin-mediated endocytosis was the 
preferred endocytic pathway for the smaller 150UiO-66 particles, whereas in the case of the larger 
260UiO-66 particles, caveolae-mediated endocytosis became to play a more important role, and a 
combined pathway uptake was observed. Additionally, the internalization of the larger 260UiO-66 
particles was a more efficient – but slower – process compared with the uptake of the smaller 
150UiO-66. More importantly, 150UiO-66 was localized mainly in lysosomes compared with larger 
UiO-66 particles, which seems to bypass them. This difference is critical when designing new MOF 
drug delivery systems since lysosome activity may prevent the MOF action before degradation. All 
these results stress the importance of studying the internalization process of nanocarriers and, more 
important, the final fate of them. In this work we have shown for the first time the importance of a 
balance between the size of MOFs for drug delivery in terms of efficiency, and where these 
particles end up inside cells, all in the efforts to increase the potential of MOFs for drug delivery 
applications. This contribution will allow selecting the optimal properties of MOFs in order to 
improve their efficiency for drug delivery.     
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4. Experimental Section  
Materials: ZrCl4 (99.5 %) and terephthalic acid (98 %) were bought from Alfa Aesar (UK). Benzoic 
acid (99.5 %), HCl (37%), Dimethylformamide (DMF, 99.8 %)), methanol (99.9 %), acetone 
(99.9 %), nystatin, sucrose (99.5 %), rottlerin, calcein disodium salt, were obtained from Sigma-
Aldrich (UK). HeLa cells cells were obtained from the ATCC. Dulbecco’s modified Eagle’s 
medium (DMEM), foetal bovine serum (FBS), L-glutamine, penicillin, and streptomycin were 
purchased from Invitrogen (UK). Phosphate-Buffered Saline (PBS), trypsin–EDTA, transferrin-
AlexaFluor-633, BODIPY TR-ceramide, Texas Red-dextran, and Lysotracker®-Deep Red were 
purchased from Life Technologies™ (UK). The CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) was obtained from Promega (UK). All chemicals and biochemicals used 
were of analytical grade.  
Instruments: All PXRD data were collected in Bragg-Brentano geometry on a D8 Bruker 
diffractometer equipped with a primary Ge monochromator for Cu Kα1 and a Sol-X solid state 
detector. Collection conditions were: 2-50° in 2θ, 0.02° step size, 15 seconds/step, divergence slits 
0.2 mm, receiving slit 0.2 mm. Samples for SEM were scattered onto spectroscopically-pure carbon 
tabs (TAAB Ltd UK) mounted on aluminum stubs. They were coated with 15 nm of gold in a 
Quorum Emitech K575X sputter coater to make them electrically conductive. They were imaged in 
an FEI XL30 FEGSEM, operated at 5 keV, using an Everhart Thornley secondary electron detector. 
Colloidal analysis was determined by dynamic light scattering (DLS) with a Brookhaven Zeta Plus 
potential analyzer (detection angle of 90º and a 35 mW laser). The measurements were performed 
in phosphate-buffered saline (PBS) and growth media at room temperature. Thermogravimetric 
analysis (TGA) was performed using a TA Instruments Q-500 series thermal gravimetric analyzer, 
with the sample (0.7 - 2 mg) held on a platinum pan under a continuous flow of dry N2 gas. TGA 
curves were obtained using a heating rate of 5 °C/min and up to 600 °C. 
Synthesis and characterization: 150UiO-66 was obtain following the protocol from Zhu et al.,[22] 
where 466 mg of ZrCl4, 320 mg of terephthalic acid (BDC), 2.44 g of benzoic acid and 0.33 mL of 
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HCl 37 % were dissolved in 36 mL of DMF. The mixture was placed in a 50 mL autoclave and 
heated at 120 °C for 48 h. After cooling down to room temperature, a white powder of UiO-66 was 
harvested by centrifugation at 5500 rpm for 20 min and washed with DMF at room temperature. 
The particles were then dispersed and washed with DMF in order to remove the non-reacted BDC. 
The same procedure was repeated with acetone and then with methanol in order to remove the DMF 
solvent from the sample. Finally, the solids were dried at 80 ºC in a vacuum oven overnight.  
260UiO-66 was obtained following the procedure described by Katz et al.,[27]where 0.125 g of ZrCl4 
were dissolved in 5 ml of DMF and 1 ml of HCl (37 %), while 0.123 g of terephthalic acid (BDC) 
were dissolved in 10 ml of DMF. The two solutions were mixed in a 25 ml teflon lined autoclave 
and heated at 80 °C for 16 hours. The resulting solid was collected by centrifugation at 5500 rpm 
for 10 minutes and then washed with DMF at room temperature. The particles were then dispersed 
and washed with DMF in order to remove the non-reacted BDC. The same procedure was repeated 
with acetone and then with methanol in order to remove the DMF solvent from the sample. Finally, 
the solids were dried at 80 ºC in a vacuum oven overnight. 
Calcein loading experiments: Calcein adsorption was performed by soaking 100 mg of activated 
UiO-66 into 40 mL of methanol calcein solution (5 mg/mL) at 37 °C under orbital agitation for 4 
days. The loaded material was collected by centrifugation at 5500 rpm for 20 minutes, washed 
twice with methanol, centrifuged again for 10 minutes and dried overnight at 37°C to remove the 
solvent. The amount of calcein adsorbed was quantified by thermogravimetric analysis (TGA). 
Cell culture: HeLa cells were maintained at 37 ºC with 5 % CO2 in high rich glucose (4500 mg/L) 
Dulbecco's modified Eagle's Medium (DMEM) with phenol red supplemented with 10 % (v/v) Fetal 
Bovine Serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin. 
This was named complete DMEM (cDMEM). The cells were passaged three times a week (at 75-80 
% of confluence) at a density of 2.8 x 104 cell/cm2. 
Cytotoxicity assays: The cytotoxicity activity of the inhibitors was investigated using the 3-(4, 5-
dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
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(Promega, UK) reduction assay. The day before the experiment, cells were seeded into a 96 well 
plate at a density of 5 x 103 cells per well. Prior to the treatments, cells were washed twice with 
PBS. The inhibitors were dissolved in cDMEM at different concentrations. They were then added to 
the cells and incubated for 2 h at 37 ºC with 5 % CO2. To measure the toxicity, the cells were 
washed three times with PBS, the media was replaced with 100 µl of fresh culture media containing 
20 µl of MTS/phenazine methosulfate (in a proportion 20:1) solution, and the plate was incubated 
for 1 h at 37 ºC with 5 % CO2. The plates were read at 490 nm.  
Flow cytometry assays (FACS): In all the FACS experiments, after any treatment, the media of each 
well was aspirated and the wells were washed extensively to remove all the conditions. The cells 
were then harvested by adding 0.1 mL of trypsin and incubated for 5 min at 37 ºC with 5 % CO2. 
The cells were recovered by centrifugation, 5 min at 1200 rpm, and re-suspended in 100 µl of 
cDMEM without phenol red. Finally the samples were measure in a Cytek DxP8 analyzer 
cytometer within 30 min. The analysis of the data was done using FlowJo and Prism software. 
Energy dependence assay: HeLa cells were seeded in a Cellstar 24-well plate at a density of 5 x 104 
cell/well and incubated for 48 h at 37 ºC with 5 % CO2 in cDMEM. Then, each well was washed 
with PBS and pre-treated at either at 4 or 37 ºC (control) for 30 min. After this period, either 
cal@150UiO-66 or cal@260UiO-66 where added and incubated for 1.5 h. Subsequently, samples 
were measured by flow cytometry.  
Treatment with inhibitors: HeLa cells were seeded in a Cellstar 24-well plate at a density of 5 x 104 
cell/well and incubated for 48 h at 37 ºC with 5 % CO2 in cDMEM. Then, each well was washed 
with PBS and pre-treated with sucrose (102.7 mg/mL, 0.3 M), chlorpromazine (31.9 µg/mL, 100 
µM), nystatin (250 µg/mL), and rottlerin (2.6 µg/mL, 5 µM) for 30 min at 37 ºC. Subsequently, 
either cal@150UiO-66, cal@260UiO-66 or endocytosis tracers (transferrin-AlexaFluor-633, 25 
µg/mL; BODIPY TR-ceramide, 3.5 µg/mL; and Texas Red-dextran-10kDa, 0.5 mg/mL) were added 
and incubated for another 1.5 h. Subsequently, samples were measured by flow cytometry.  
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Kinetics of cal@UiO-66 uptake: HeLa cells were seeded in a Cellstar 24-well plate at a density of 5 
x 104 cell/well and incubated for 48 h at 37 ºC with 5 % CO2 in cDMEM. Then, each well was 
washed with PBS and incubated with 0.5 mg/mL and 0.35 mg/mL of cal@150UiO-66 and 
cal@260UiO-66 respectively for different times. Subsequently, samples were measured by flow 
cytometry.  
Lysosome formation analysis: HeLa cells were seeded in a NUNCTM imaging four-well plate at a 
density of 1.11 x 105 cell/mL and incubated for 24 h at 37 ºC with 5 % CO2 in cDMEM. The cells 
were then washed with PBS and incubated with 0.05, 0.5 and 1 mg/mL of empty 150UiO-66 or 
260UiO-66 for 2 h at 37 ºC with 5 % CO2 in cDMEM. Subsequently, cells were washed with PBS to 
remove the conditions and incubated with LysoTracker®-Deep red for another 30 min. Then, the 
cells were washed with trypan blue (0.4 %) to quench any external fluorescence and three times 
with PBS. Then, fresh media without phenol red was added to each sample. Finally, the four-well 
plate was placed on a Leica TCS SP5 confocal microscope to be imaged. The microscope was 
equipped with 405 diode, argon and HeNe lasers. Leica LAS AF software was used to analyze the 
images. 
Co-localization experiments: For all the co-localization experiments HeLa cells were seeded in a 
NUNCTM imaging four-well plate at a density of 1.11 x 105 cell/mL and incubated for 24 h at 37 ºC 
with 5 % CO2 in cDMEM. At the end the four-well plate was placed on a Leica TCS SP5 confocal 
microscope to be imaged. The microscope was equipped with 405 diode, argon and HeNe lasers. 
Leica LAS AF software was used to analyze the images. To quantify co-localization a minimum of 
4 and a maximum of 7 images were analyzed from each experiment. The images were analyzed 
using a co-localization plug-in on ImageJ (JaCOP[41]). 
Tracers: The cells were then washed with PBS and incubated with 0.5 mg/mL of cal@150UiO-66 or 
0.35 mg/mL of cal@260UiO-66 along with either transferrin (100 µg/mL), ceramide (3.5 µg/mL) or 
dextran-10 kDa (0.5 mg/mL) for another 24 h at 37 ºC with 5 % CO2 in cDMEM. Subsequently, the 
cells were washed with PBS to remove the conditions, with trypan blue (0.4 %) to quench any 
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external fluorescence, and again three times with PBS. Finally, fresh cDMEM without phenol red 
was added to each sample.  
LysoTracker®-Deep red: The cells were then washed with PBS and incubated with 0.5 mg/mL of 
cal@150UiO-66 or 0.35 mg/mL of cal@260UiO-66 along with LysoTracker®-Deep red for 2 h at 37 
ºC with 5 % CO2 in cDMEM. Subsequently, the cells were washed with PBS to remove the 
conditions, with trypan blue (0.4 %) to quench any external fluorescence, and again three times with 
PBS. Finally, fresh media without phenol red was added to each sample.  
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
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The study of the uptake mechanism and final fate of a promising metal-organic framework 
(MOF) is a crucial step for optimizing these materials for drug delivery applications. UiO-66 
particles of 260 nm are able of partially bypass the acidic degradation in the lysosomes whereas 
particles of 150 nm are destroyed in this compartment.  
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S1. Powder X-Ray Diffraction (PXRD) 
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Figure S1. Powder X-ray diffraction (PXRD) patterns of synthesized 150UiO-66 and 260UiO-66, cal@150UiO-66 
and cal@260UiO-66 compared with the calculated one for UiO-66. 
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S2. Scanning electron microscopy (SEM) 
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Figure S2. SEM images for a) 150UiO-66 , and b) 260UiO-66. 
 
 
S3. Diffraction light scattering (DLS) measurements 
It is possible to see from figure S3 that the material of both particles sizes aggregates 
more when is in PBS solution compared with the values in growth media. This less 
aggregation is probably the result of the interaction of the material with proteins present in 
growth media and not in PBS. 
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Figure S3. Particle size analysis images for: PBS (black), and growth media (white). 
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S4. Thermogravimetric analysis (TGA) 
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Figure S4. TGA curves under dry N2 gas of UiO-66, black solid line; cal@150UiO-66, red solid line; 
cal@150UiO-66, blue solid line; and free calcein, green solid line. 
 
 
 
